LRRK2 and Parkinson disease: For example, since pre-clinical LRRK2 therapeutics have generally only been tested before or coincident with the toxic insults that form the basis of parkinsonian models, it remains to be determined whether such strategies will also be effective if started once the degenerative process is already well underway, such as at the time of clinical diagnosis of PD.